Spots Global Cancer Trial Database for aprepitant
Every month we try and update this database with for aprepitant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer | NCT01046461 | Solid Tumour Postoperative N... | Ramosetron, Apr... | 18 Years - 75 Years | Hallym University Medical Center | |
| Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors | NCT00572572 | Germ Cell Tumor... | Aprepitant Placebo | 15 Years - | Hoosier Cancer Research Network | |
| Fosaprepitant in Patients Receiving Ifosfamide-based Regimen | NCT01490060 | Sarcoma Chemotherapy-in... Effects of Chem... Adverse Effects... | Fosaprepitant Dexamethasone 5HT3 receptor a... Ifosfamide-base... Doxorubicin Mesna Ifosfamide Vincristine | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy | NCT03674294 | Gastrointestina... Chemotherapy-in... | Aprepitant Palonosetron Dexamethasone Placebo Oral Ta... | 18 Years - 50 Years | Sun Yat-sen University | |
| Aprepitant in the Management of Biological Therapies-related Severe Pruritus | NCT01683552 | ITCH | Aprepitant Prednisone Fexofenadine | 18 Years - 85 Years | Campus Bio-Medico University | |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) | NCT01640340 | Malignant Neopl... | aprepitant palonosetron hy... ondansetron dexamethasone | 18 Years - 88 Years | Ohio State University Comprehensive Cancer Center | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | NCT05841849 | Breast Cancer Chemotherapy-in... | Aprepitant Palonosetron Fosaprepitant | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer | NCT01017809 | Ovarian Cancer | Aprepitant | 18 Years - | NYU Langone Health | |
| Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy | NCT00169572 | Nausea and Vomi... Chemotherapy-In... | Aprepitant Ondansetron GW679769 Dexamethasone | 18 Years - | GlaxoSmithKline | |
| A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation | NCT02576327 | Vomiting | Tropisetron Dexamethasone Aprepitant | 18 Years - 65 Years | Peking University | |
| Efficacy of Aprepitant (Emend®) in Children | NCT01661335 | Nausea Vomiting Childhood Cance... | Ondansetron, de... Ondansetron, De... | 6 Months - 20 Years | University of Oklahoma | |
| Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma | NCT03514381 | Soft Tissue Sar... | Patients starti... | 18 Years - | Institut Claudius Regaud | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer | NCT00719173 | Breast Cancer Nausea and Vomi... | aprepitant cyclophosphamid... placebo | 18 Years - 120 Years | UNC Lineberger Comprehensive Cancer Center | |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) | NCT01640340 | Malignant Neopl... | aprepitant palonosetron hy... ondansetron dexamethasone | 18 Years - 88 Years | Ohio State University Comprehensive Cancer Center | |
| Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment | NCT02646020 | Non-small Cell ... | Aprepitant Desloratadine Placebo of apre... Placebo of desl... | 18 Years - | Sun Yat-sen University | |
| Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers | NCT02161991 | Carcinoma, Non-... | Aprepitant placebo | 18 Years - 75 Years | Hunan Province Tumor Hospital | |
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | NCT05841849 | Breast Cancer Chemotherapy-in... | Aprepitant Palonosetron Fosaprepitant | 18 Years - 70 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | NCT01851369 | Lymphomas Solid Tumors NSCLC Metastatic Colo... Granulosa Cell ... | TRC102 CT scan Lomotil Prochlorperazin... Metoclopramide 5-HT3 antagonis... Aprepitant Biopsy | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis | NCT02336750 | Breast Cancer | Aprepitant Mirtazapine | 18 Years - | Fudan University | |
| Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC | NCT03572829 | Vomiting Nausea Post Che... Head Neck Cance... | Aprepitant | 18 Years - 80 Years | ChineseAMS | |
| Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy | NCT00169572 | Nausea and Vomi... Chemotherapy-In... | Aprepitant Ondansetron GW679769 Dexamethasone | 18 Years - | GlaxoSmithKline | |
| Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC) | NCT01640340 | Malignant Neopl... | aprepitant palonosetron hy... ondansetron dexamethasone | 18 Years - 88 Years | Ohio State University Comprehensive Cancer Center | |
| Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients | NCT00588835 | Tumor | aprepitant Dexamethasone a... | 18 Years - 75 Years | Radboud University Medical Center | |
| Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients | NCT04873284 | Chemotherapy In... Pediatric Cance... | fosaprepitant aprepitant Granisetron plu... | 2 Years - 12 Years | Shanghai Children's Medical Center | |
| Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer. | NCT01298193 | Breast Cancer | Aprepitant | 18 Years - | Spanish Breast Cancer Research Group | |
| Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients | NCT00869973 | Emesis | Aprepitant dexamethasone | 18 Years - | S. Maria Hospital, Terni | |
| Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX | NCT00381862 | Colorectal Canc... Nausea and Vomi... | aprepitant dexamethasone fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin palonosetron hy... quality-of-life... | 18 Years - 120 Years | OHSU Knight Cancer Institute | |
| Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide | NCT01450826 | Nausea Vomiting Glioma | aprepitant ondansetron | 18 Years - | Duke University | |
| Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630) | NCT00871910 | Solid Tumors Lymphoma, Non-H... Multiple Myelom... | SCH 727965 SCH 727965 SCH 727965 SCH 727965 Aprepitant Ondansetron Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting | NCT01432015 | Ovarian Cancer Uterine Cancer | fosaprepitant aprepitant Oral Placebo IV placebo | 18 Years - | Gynecologic Oncology Associates | |
| Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial | NCT00475085 | Nausea | aprepitant dexamethasone granisetron hyd... palonosetron hy... prochlorperazin... placebo | 18 Years - | University of Rochester | |
| Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC | NCT03572829 | Vomiting Nausea Post Che... Head Neck Cance... | Aprepitant | 18 Years - 80 Years | ChineseAMS | |
| A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer | NCT02364804 | Non-small Cell ... | Aprepitant | 20 Years - 79 Years | Shiga University | |
| A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC) | NCT01636947 | Nausea Vomiting | Aprepitant Aprepitant Plac... Ondansetron Dexamethasone Ondansetron Pla... Rescue Therapy ... | 21 Years - | Merck Sharp & Dohme LLC | |
| Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone | NCT01536691 | Cancer Malignancy | ramosetron ondansetron | 20 Years - | Hallym University Medical Center | |
| Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | NCT00954941 | Hematologic Dis... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... | Ondansetron Aprepitant | 18 Years - | M.D. Anderson Cancer Center | |
| Multi-day Doses in Prevention of Nausea and Emesis | NCT00600353 | Myeloma, Plasma... Lymphoma, Malig... | Palonosetron Aprepitant Dexamethasone | 18 Years - | University of Kansas Medical Center | |
| A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer | NCT02364804 | Non-small Cell ... | Aprepitant | 20 Years - 79 Years | Shiga University | |
| Efficacy of Aprepitant (Emend®) in Children | NCT01661335 | Nausea Vomiting Childhood Cance... | Ondansetron, de... Ondansetron, De... | 6 Months - 20 Years | University of Oklahoma | |
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma | NCT02770378 | Glioblastoma | Temozolomide Aprepitant Minocycline Disulfiram Celecoxib Sertraline Captopril Itraconazole Ritonavir Auranofin | 18 Years - | University of Ulm |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
